$30 Billion Deal, page-3013

Not sure what you mean there,
The latest Phase II Covid Trials that we are awaiting results for were on Humans:

16 August 2023
COMPLETION OF PHASE 2 COVID CLINICAL TRIAL

The Directors of Biotron Limited (‘Biotron’ or ‘the Company’ ) are pleased to advise that all participants in the Phase 2 COVID-19 clinical trial of the Company’s antiviral drug BIT225 have completed dosing, marking the end of the clinical phase of the study. As previously advised, the design of the Phase 2, double blind, placebo-controlled clinical trial (BIT225-012) was based on guidance received during 2022 from the US Food and Drug Administration (FDA). The trial aims to determine if 7 days of treatment with BIT225 commenced within 3 days of onset of COVID-19 symptoms results in reduction in SARS-CoV-2 blood viral load, clinically favourable changes in viral, inflammatory and immune activation markers, as well as improvement in clinical symptoms of COVID-19.

REPORT ON ACTIVITIES FOR THE QUARTER ENDED 30 SEPTEMBER 2023

Biotron Limited (‘Biotron’ or ‘the Company’ ) has achieved key outcomes including:

 Completed a Phase 2 trial of BIT225 (BIT225-012) for treatment of adults with COVID-19 at sites in Thailand following receipt of approvals from relevant ethics and regulatory authorities.

SARS-CoV-2/COVID-19 Program

During the quarter ended 30 September 2023,
the Company completed a Phase 2 clinical trial (BIT225- 012) with its lead antiviral drug BIT225 for treatment of COVID-19 at sites in Thailand.
The trial commenced in May 2023 and was very quickly fully enrolled
with dosing completed in August 2023.